Russell DDS - BIOLASE Chief Officer
| BIOLDelisted Stock | USD 0.05 0.02 27.46% |
Insider
Russell DDS is Chief Officer of BIOLASE
| Phone | 949 361 1200 |
| Web | https://www.biolase.com |
BIOLASE Management Efficiency
The company has return on total asset (ROA) of (0.2682) % which means that it has lost $0.2682 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.0476) %, meaning that it created substantial loss on money invested by shareholders. BIOLASE's management efficiency ratios could be used to measure how well BIOLASE manages its routine affairs as well as how well it operates its assets and liabilities.BIOLASE currently holds 17.91 M in liabilities with Debt to Equity (D/E) ratio of 1.07, which is about average as compared to similar companies. BIOLASE has a current ratio of 2.41, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about BIOLASE's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Todd Huntsman | Vivos Therapeutics | N/A | |
| Ryan Sabia | Tivic Health Systems | 37 | |
| Marina Feler | Nano X Imaging | 35 | |
| Jereme Sylvain | DexCom Inc | 44 | |
| CPA CPA | NanoVibronix | 68 | |
| Danielle Watson | Heart Test Laboratories | 42 | |
| Julie Gannon | Vivos Therapeutics | N/A | |
| Natalie Welch | Pacific Biosciences of | N/A | |
| Veronica Cai | Tivic Health Systems | 48 | |
| Bradford Amman | Vivos Therapeutics | 62 | |
| Christopher Yamamoto | Bioventus | N/A | |
| Ilung Kim | Nano X Imaging | 65 | |
| Tal Shank | Nano X Imaging | 46 | |
| Paul Flynn | DexCom Inc | 55 | |
| Gilad Yron | Nano X Imaging | 51 | |
| Kenneth Reali | Bioventus | 58 | |
| James Dara | Nano X Imaging | 54 | |
| Erez Meltzer | Nano X Imaging | 67 | |
| Sean Christensen | DexCom Inc | N/A | |
| Susan Kim | Pacific Biosciences of | 48 | |
| Trevin Rard | Pacific Biosciences of | N/A | |
Management Performance
| Return On Equity | -5.05 | |||
| Return On Asset | -0.27 |
BIOLASE Leadership Team
Elected by the shareholders, the BIOLASE's board of directors comprises two types of representatives: BIOLASE inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BIOLASE. The board's role is to monitor BIOLASE's management team and ensure that shareholders' interests are well served. BIOLASE's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BIOLASE's outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Rodriguez, Director Events | ||
| Jennifer Bright, Chief Officer | ||
| Matthew Wilson, Vice President of Human Resources | ||
| John Beaver, CFO, Senior Vice President | ||
| Russell DDS, Chief Officer | ||
| Michael Carroll, Corporate Secretary | ||
| Steven Sandor, Chief Officer |
BIOLASE Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BIOLASE a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -5.05 | |||
| Return On Asset | -0.27 | |||
| Profit Margin | (0.44) % | |||
| Operating Margin | (0.45) % | |||
| Current Valuation | 13.65 M | |||
| Shares Outstanding | 33.4 M | |||
| Shares Owned By Insiders | 0.32 % | |||
| Shares Owned By Institutions | 8.97 % | |||
| Number Of Shares Shorted | 2.1 M | |||
| Price To Earning | (7.23) X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Other Consideration for investing in BIOLASE Stock
If you are still planning to invest in BIOLASE check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the BIOLASE's history and understand the potential risks before investing.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |